NCT07173933尚未招募1 期
A Multicenter, Open-label, Single-dose, Dose-escalation Phase I/II Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GC310 Adeno-associated Virus Injection in the Treatment of Patients With Wilson's Disease (WD)
GeneCradle Inc2 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2025年10月1日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- Incidence of adverse events after GC310 administration
研究概览
简要总结
The goal of this clinical trial is to learn if GC310 (AAV5-ATP7B) gene therapy can treat Wilson's Disease (WD) in patients over the age of 18 years old. The main questions it aims to answer are:
Is GC310 safe and tolerable to WD patients? What is the recommended phase II dose (RP2D)? What is the change from baseline in 24-hour urinary copper concentration after 52 weeks of administration?
Participants will be administrated GC310 intravenously and be followed up for 52 weeks to observe drug safety, tolerability and efficacy .
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged ≥ 18 years, sex unrestricted;
- •Definitive diagnosis of Wilson disease (WD) based on:
- •(i) or (ii) + (iii) and (iv), or (i) or (ii) + (v); (i) Neurological and/or psychiatric symptoms; (ii) Unexplained liver injury; (iii) Reduced serum ceruloplasmin and/or elevated 24-hour urinary copper; (iv) Positive corneal Kayser-Fleischer (K-F) ring; (v) Biallelic pathogenic ATP7B variants confirmed by segregation analysis and variant pathogenicity assessment;
- •Serum ceruloplasmin concentration < ½ × lower limit of normal (LLN);
- •Willing and able to comply with all study procedures, and has provided written informed consent.
排除标准
- •Subjects meeting ANY of the following criteria will be excluded:
- •Screening serum anti-AAV5 neutralizing antibody titre > 1:
- •Clinically significant laboratory abnormality at screening or baseline:
- •ALT or AST ≥ 5 × ULN, direct bilirubin > 1 × ULN, or albumin < 1 × LLN;
- •Blood ammonia > 1 × ULN.
- •Renal impairment (any degree).
- •Current hepatic decompensation or history of hepatic decompensation.
- •Liver stiffness measurement (LSM) ≥ 15 kPa by transient elastography at screening.
- •History of acute liver failure from any cause.
- •Evidence of advanced liver disease defined by either:
- •MELD score ≥ 12, or
- •Child-Pugh score ≥
- •Severe neuro-psychiatric manifestations that, in the investigator's opinion, could compromise subject safety or interfere with study participation.
- •Positive for HIV antibody, hepatitis C antibody, Treponema pallidum antibody, or hepatitis B surface antigen.
- •Contraindications to glucocorticoid therapy judged by the investigator (e.g., uncontrolled hypertension, systemic fungal infection, glaucoma, osteoporosis, active tuberculosis).
- •Concurrent conditions that may interfere with study conduct or assessment, including significant gastrointestinal, cardiovascular, cerebrovascular, renal, endocrine, haematological, immunological, neurological or psychiatric disorders other than Wilson disease.
- •Pregnant or lactating women.
- •Women of child-bearing potential or fertile men who plan to conceive within 1 year after dosing or are unwilling to use highly effective contraception.
- •Body-mass index ≥ 24 kg/m².
- •History of severe hypersensitivity to foods or drugs, including recombinant proteins.
- •Vaccination within 2 weeks prior to planned dosing.
- •Prior exposure to any gene-therapy product.
- •Participation in any other clinical trial (WD-related or not) within 3 months before screening.
- •Any other condition or circumstance that, in the opinion of the investigator, renders the subject unsuitable for the study (e.g., poor compliance).
结局指标
主要结局
Incidence of adverse events after GC310 administration
时间窗: within 12 weeks
Incidence of dose-limiting toxicity (DLT) events after GC310 administration;
时间窗: within 4 weeks
Change from baseline in serum ceruloplasmin (CP) concentration after GC310 administration;
时间窗: 52 weeks
Change from baseline in 24-hour urinary copper excretion after GC310 administration.
时间窗: 52 weeks
次要结局
- Evaluation of adverse-event incidence(52 weeks)
- Change from baseline in the urinary copper-to-creatinine ratio(52 weeks)
- Change from baseline in ALT and AST levels(52 weeks)
- Change from baseline in Kayser-Fleischer (K-F) rings observed by slit-lamp examination(52 weeks)
- Change from baseline in hepatic imaging findings(52 weeks)
- Serum anti-AAV5 and anti-ATP7B antibody levels(52 weeks)
- Change in blood GC310 vector genome copy number(52 weeks)
- AAV shedding(52 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 MutationOptic, Atrophy, Hereditary, LeberNCT02652767GenSight Biologics39
已完成
3 期
Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)Optic, Atrophy, Hereditary, LeberNCT02652780GenSight Biologics37
已完成
2 期
A Study to Treat Patients Whose Chronic Angina Symptoms Are Not Relieved by Medication and Have an Area of the Heart That Cannot be Treated by Standard TherapiesModerate to Severe Angina PectorisNCT00215696GenVec129
招募中
1 期
GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle GlaucomaNCT06921317IVIEW Therapeutics Inc.6
已完成
1 期
A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By InjectionPulmonary Disease, Chronic ObstructiveNCT00711126GlaxoSmithKline9